Anal Fissure Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Anal Fissure Therapeutics Market is segmented By Treatment (Nitrate Ointment, Calcium Channel Blockers, Botox Injections, Others) By Route of administration (Oral, Topical, Others) By Distribution channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Anal Fissure Therapeutics Market Size

The Global Anal Fissure Therapeutics Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031. 

An anorectal condition marked by inflammation or tearing of the lining of the lower rectum is known as an anal fissure. During bowel movements, it causes considerable discomfort and blood. The ailment is not life-threatening, but it has a major impact on a person's quality of life.

This can help increase blood flow to the fissure and promote healing. It also can help relax the anal sphincter. The majority of chronic anal fissures can be treated effectively by local application of isosorbide dinitrate.

Moreover, the market is driven by factors such as the rising cases of acquired immunodeficiency syndrome, the increasing prevalence of anal fissures, and rising awareness among the people.

Anal Fissure Therapeutics Market Summary

For more details on this report - Request for Sample

Anal Fissure Therapeutics Market Trends

Drivers

Rising Cases of Acquired Immunodeficiency Syndrome 

The demand for the anal fissure therapeutics market is driven by multiple factors. Growing awareness of various treatment choices, advancements in medications and surgical processes like laser therapy, and a reduction in the social stigma associated with its treatment contribute to the market's expansion. 

Rising TB cases, cancer, acquired immunodeficiency syndrome (AIDS), and inflammatory bowel disease. Furthermore, hormonal changes in pregnant women promote constipation, which leads to anal fissures. Anal fissures can also be caused by childbirth stress. Other risk factors include anal sex, ulcerative colitis, and Crohn's disease.

Moreover, Constipation is common among Americans. Constipation affects almost everyone at some point in their lives, with a recent poll revealing that 16% of Americans and one-third of those over 60 suffer from chronic constipation. These factors are likely to boost the anal fissure therapeutics market.

In addition, key players in the industry launched new products that would drive the market growth. For instance, in January 2021, Ipsen reported that in 5 therapeutic indications, a sizable fraction of patients treated with its Dysport (abobotulinumtoxinA) did not necessitate retreatment.

Also, in May 2022, MOVICOL HD, a medication to treat chronic constipation, was introduced in Japan by Eisai Co., Ltd., and Mochida Pharmaceutical Co., Ltd., Adults and children of 2 years of age and older are prescribed to use it.

Restraints

Factors such as product recalls, the harmful adverse effects of medication, the high cost associated with the procedures, and the lack of awareness about anal fissure treatment are expected to hamper the market.

Anal Fissure Therapeutics Market Segment Analysis

The anal fissure therapeutics market is segmented based on treatment, route of administration, distribution channel, and region.

The calcium channel blockers segment accounted for approximately 49.5% of the anal fissure therapeutics  market share

The calcium channel blockers segment is expected to hold the largest market share over the forecast period. Calcium channel blockers are antihypertensive medicines. They function by blocking calcium from entering the heart and artery cells. Calcium causes the heart and arteries to constrict more tightly. 

Calcium channel blockers allow blood arteries to relax and open by inhibiting calcium.  Infants and middle-aged people are the most commonly affected by anal fissures. Every year, around 235,000 new cases of an anal fissure are reported in the United States.

As per NHS news in November 2024, topical calcium channel blockers work by relaxing the sphincter muscle and increasing blood supply to the fissure. CCBs, such as diltiazem or nifedipine, lower blood pressure and ease anal sphincter spasms. One calcium channel blocker is nifedipine (CCB). It functions in anal fissures by preventing calcium from acting on the anus's blood vessels.

Anal Fissure Therapeutics Market Geographical Share

North America accounted for approximately 42.3% of the anal fissure therapeutics   market share 

North America region is expected to hold the largest market share over the forecast period due to the region's rapid implementation of innovative technologies, a substantial percentage of individuals living with inflammatory bowel diseases, and the major investments made to the healthcare system by the public and private sectors.

According to the Mayo Clinic's 2022 report, more than 1,000 patients receive surgery for anal fistulas each year, demonstrating the doctors' considerable experience in managing these conditions in the United States. Furthermore, it is projected that continuous developments in the field of anal fissure therapy in North America will support market expansion throughout the projected period

Owing to the widespread use of advanced treatment. Another significant market driver is the high rate of blockage among patients. According to the American Gastroenterological Association, about 60% of Americans suffer from this illness. Medicines required for rapid recovery are likely to accelerate the growth of the anal fissure treatment market.

The North American region is developing novel treatment alternatives. Furthermore, rising death rates increased patient awareness about the disease. Advanced healthcare infrastructure is expected to drive the growth of the anal fissure therapeutics market in North America.

Moreover, major player's strategies such as partnerships and collaboration would propel the market growth. AstraZeneca Plc, a pharmaceutical and biotechnology company headquartered in the UK that specializes in the research and marketing of prescription pharmaceuticals, acquired Alexion Pharmaceuticals Inc. in July 2021.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the anal fissure therapeutics market. The pandemic has hampered progress in several countries across multiple disciplines. The COVID-19 outbreak continued to harm important major participants in the anal fissure treatment industry.

However, many producers are struggling due to supply chain delays caused by lockdowns in various nations in the third quarter. However, the negative impact is being partially compensated in several ways, such as utilizing numerous distribution alternatives and online channels.

Anal Fissure Therapeutics Market Key Players

The major global players in the anal fissure therapeutics market include Takeda Pharmaceuticals, Manus Aktteva, Pfizer, AbbVie, Pfizer, Farmacosmo, Silvergate Pharmaceuticals, Covis Pharmaceuticals, Novartis AG, Trumachealthcare, Taj Pharmaceuticals, among others.

Key Developments

• On March 1, 2024, Nitroglycerin ointment is an excellent treatment for anal fissure because many patients prefer to forgo surgery; Glyceryl trinitrate topical treatment has been shown in studies to reduce maximum anal resting pressures in patients with a range of anal pathologies. 
• On February 13, 2024, Ossium Health, Inc. to treat refractory perianal fistulas in Crohn's disease patients, submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA). 
• On October 18, 2023, Takeda announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based on topline data. 
•  On February 16, 2022, Takeda filed a new drug application in Japan to manufacture and market. Darvadstrocel for the treatment of complex perianal fistulas in adult Crohn's disease patients.

Why Purchase the Report?

• To visualize the anal fissure therapeutics market segmentation based on treatment, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of anal fissure therapeutics market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Treatment mapping is available in excel consisting of key treatments of all the major players.

The anal fissure therapeutics market report would provide approximately 65 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies